We’re thrilled to say that we’ve recruited our first patient onto our META 3 trial.
This is a randomised placebo-controlled double-blind phase III trial to determine the effects of metformin versus placebo on the incidence of diabetes in HIV-infected persons with pre-diabetes in Tanzania. It has taken a herculean effort to get to this stage, and so we’d like to say huge congratulations and thank you to everyone involved in reaching this important milestone!